THU0599 Evaluation of efficacy and safety of canakinumab in japanese patients with systemic juvenile idiopathic arthritis in phase iii clinical trial, composed predominantly of patients with prior use of tocilizumab
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.2464
Abstract: Background Systemic juvenile idiopathic arthritis (SJIA) is a distinct form of juvenile idiopathic arthritis (JIA), accounting for approximately 4% to 17% of JIA1. In Japan, a higher frequency of SJIA, 41.7% of JIA2 has been… read more here.
Keywords: use tocilizumab; juvenile idiopathic; pts achieved; idiopathic arthritis ... See more keywords